Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H25NOS |
Molecular Weight | 315.473 |
Optical Activity | ( - ) |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCN(CCC1=CC=CS1)[C@H]2CCC3=C(C2)C=CC=C3O
InChI
InChIKey=KFQYTPMOWPVWEJ-INIZCTEOSA-N
InChI=1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3/t16-/m0/s1
Molecular Formula | C19H25NOS |
Molecular Weight | 315.473 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.drugs.com/mtm/rotigotine-transdermal.html
http://www.rxlist.com/neupro-drug.htm
http://www.wikidoc.org/index.php/Rotigotine
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/mtm/rotigotine-transdermal.html
http://www.rxlist.com/neupro-drug.htm
http://www.wikidoc.org/index.php/Rotigotine
Rotigotine is an agonist at all 5 dopamine receptor subtypes (D1-D5) but binds to the D3 receptor with the highest affinity. It is also an antagonist at α-2-adrenergic receptors and an agonist at the 5HT1A receptors. Rotigotine also inhibits dopamine uptake and prolactin secretion. It is FDA approved for the treatment of Parkinson's disease, restless legs syndrome. Dopamine antagonists, such as antipsychotics or metoclopramide, may diminish the effectiveness of Rotigotine. Common adverse reactions include nausea, vomiting, somnolence, application site reactions, dizziness, anorexia, hyperhidrosis, insomnia and dyskinesia.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18704368 |
13.5 nM [Ki] | ||
83.0 nM [Ki] | |||
Target ID: CHEMBL1850 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18704368 |
5.4 nM [Ki] | ||
Target ID: CHEMBL219 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18704368 |
15.0 nM [Ki] | ||
Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18704368 |
30.0 nM [Ki] | ||
Target ID: CHEMBL1942 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18704368 |
27.0 nM [Ki] | ||
Target ID: CHEMBL234 |
0.7 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | NEUPRO Approved UseNEUPRO is a dopamine agonist indicated for the treatment of: Parkinson's disease (1.1) Moderate-to-severe primary Restless Legs Syndrome (1.2) 1.1 Parkinson's Disease (PD) NEUPRO is indicated for the treatment of Parkinson's disease. 1.2 Restless Legs Syndrome (RLS) NEUPRO is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome. Launch Date2007 |
|||
Primary | NEUPRO Approved UseNEUPRO is a dopamine agonist indicated for the treatment of: Parkinson's disease (1.1) Moderate-to-severe primary Restless Legs Syndrome (1.2) 1.1 Parkinson's Disease (PD) NEUPRO is indicated for the treatment of Parkinson's disease. 1.2 Restless Legs Syndrome (RLS) NEUPRO is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome. Launch Date2007 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.34 ng/mL |
3 mg 2 times / day steady-state, transdermal dose: 3 mg route of administration: Transdermal experiment type: STEADY-STATE co-administered: |
ROTIGOTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.63 ng × h/mL |
3 mg 2 times / day steady-state, transdermal dose: 3 mg route of administration: Transdermal experiment type: STEADY-STATE co-administered: |
ROTIGOTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.5 h |
3 mg 2 times / day steady-state, transdermal dose: 3 mg route of administration: Transdermal experiment type: STEADY-STATE co-administered: |
ROTIGOTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10% |
unknown |
ROTIGOTINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
54 mg 1 times / day multiple, topical Highest studied dose Dose: 54 mg, 1 times / day Route: topical Route: multiple Dose: 54 mg, 1 times / day Sources: Page: p.10 |
unhealthy, 29 - 88 n = 130 Health Status: unhealthy Condition: Advanced-stage Parkinson’s disease Age Group: 29 - 88 Sex: M+F Population Size: 130 Sources: Page: p.10 |
|
24 mg 1 times / day multiple, topical Studied dose Dose: 24 mg, 1 times / day Route: topical Route: multiple Dose: 24 mg, 1 times / day Sources: Page: p.196 |
unhealthy, 68.8 n = 26 Health Status: unhealthy Condition: Advanced-stage Parkinson’s disease Age Group: 68.8 Sex: M+F Population Size: 26 Sources: Page: p.196 |
Disc. AE: Abnormal ECG, Hypertension... AEs leading to discontinuation/dose reduction: Abnormal ECG (mild, 3.85%) Sources: Page: p.196Hypertension (mild, 3.85%) Sensory hallucinations (moderate, 3.85%) Application site reaction (moderate, 7.7%) |
8 mg 1 times / day multiple, topical Recommended Dose: 8 mg, 1 times / day Route: topical Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Advanced-stage Parkinson’s disease Sources: Page: p.1 |
Disc. AE: Allergic reaction, Somnolence... AEs leading to discontinuation/dose reduction: Allergic reaction Sources: Page: p.1Somnolence Hallucinations Psychotic behavior Dyskinesia Hypotension symptomatic Syncope Blood pressure increased Tachycardia Impulse-control disorder Compulsive personality disorder Daytime sleepiness |
8 mg 1 times / day multiple, topical Recommended Dose: 8 mg, 1 times / day Route: topical Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.1, p.5 |
unhealthy Health Status: unhealthy Condition: Advanced-stage Parkinson’s disease Sources: Page: p.1, p.5 |
Disc. AE: Application site reaction... AEs leading to discontinuation/dose reduction: Application site reaction (2%) Sources: Page: p.1, p.5 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abnormal ECG | mild, 3.85% Disc. AE |
24 mg 1 times / day multiple, topical Studied dose Dose: 24 mg, 1 times / day Route: topical Route: multiple Dose: 24 mg, 1 times / day Sources: Page: p.196 |
unhealthy, 68.8 n = 26 Health Status: unhealthy Condition: Advanced-stage Parkinson’s disease Age Group: 68.8 Sex: M+F Population Size: 26 Sources: Page: p.196 |
Hypertension | mild, 3.85% Disc. AE |
24 mg 1 times / day multiple, topical Studied dose Dose: 24 mg, 1 times / day Route: topical Route: multiple Dose: 24 mg, 1 times / day Sources: Page: p.196 |
unhealthy, 68.8 n = 26 Health Status: unhealthy Condition: Advanced-stage Parkinson’s disease Age Group: 68.8 Sex: M+F Population Size: 26 Sources: Page: p.196 |
Sensory hallucinations | moderate, 3.85% Disc. AE |
24 mg 1 times / day multiple, topical Studied dose Dose: 24 mg, 1 times / day Route: topical Route: multiple Dose: 24 mg, 1 times / day Sources: Page: p.196 |
unhealthy, 68.8 n = 26 Health Status: unhealthy Condition: Advanced-stage Parkinson’s disease Age Group: 68.8 Sex: M+F Population Size: 26 Sources: Page: p.196 |
Application site reaction | moderate, 7.7% Disc. AE |
24 mg 1 times / day multiple, topical Studied dose Dose: 24 mg, 1 times / day Route: topical Route: multiple Dose: 24 mg, 1 times / day Sources: Page: p.196 |
unhealthy, 68.8 n = 26 Health Status: unhealthy Condition: Advanced-stage Parkinson’s disease Age Group: 68.8 Sex: M+F Population Size: 26 Sources: Page: p.196 |
Allergic reaction | Disc. AE | 8 mg 1 times / day multiple, topical Recommended Dose: 8 mg, 1 times / day Route: topical Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Advanced-stage Parkinson’s disease Sources: Page: p.1 |
Blood pressure increased | Disc. AE | 8 mg 1 times / day multiple, topical Recommended Dose: 8 mg, 1 times / day Route: topical Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Advanced-stage Parkinson’s disease Sources: Page: p.1 |
Compulsive personality disorder | Disc. AE | 8 mg 1 times / day multiple, topical Recommended Dose: 8 mg, 1 times / day Route: topical Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Advanced-stage Parkinson’s disease Sources: Page: p.1 |
Daytime sleepiness | Disc. AE | 8 mg 1 times / day multiple, topical Recommended Dose: 8 mg, 1 times / day Route: topical Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Advanced-stage Parkinson’s disease Sources: Page: p.1 |
Dyskinesia | Disc. AE | 8 mg 1 times / day multiple, topical Recommended Dose: 8 mg, 1 times / day Route: topical Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Advanced-stage Parkinson’s disease Sources: Page: p.1 |
Hallucinations | Disc. AE | 8 mg 1 times / day multiple, topical Recommended Dose: 8 mg, 1 times / day Route: topical Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Advanced-stage Parkinson’s disease Sources: Page: p.1 |
Hypotension symptomatic | Disc. AE | 8 mg 1 times / day multiple, topical Recommended Dose: 8 mg, 1 times / day Route: topical Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Advanced-stage Parkinson’s disease Sources: Page: p.1 |
Impulse-control disorder | Disc. AE | 8 mg 1 times / day multiple, topical Recommended Dose: 8 mg, 1 times / day Route: topical Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Advanced-stage Parkinson’s disease Sources: Page: p.1 |
Psychotic behavior | Disc. AE | 8 mg 1 times / day multiple, topical Recommended Dose: 8 mg, 1 times / day Route: topical Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Advanced-stage Parkinson’s disease Sources: Page: p.1 |
Somnolence | Disc. AE | 8 mg 1 times / day multiple, topical Recommended Dose: 8 mg, 1 times / day Route: topical Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Advanced-stage Parkinson’s disease Sources: Page: p.1 |
Syncope | Disc. AE | 8 mg 1 times / day multiple, topical Recommended Dose: 8 mg, 1 times / day Route: topical Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Advanced-stage Parkinson’s disease Sources: Page: p.1 |
Tachycardia | Disc. AE | 8 mg 1 times / day multiple, topical Recommended Dose: 8 mg, 1 times / day Route: topical Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Advanced-stage Parkinson’s disease Sources: Page: p.1 |
Application site reaction | 2% Disc. AE |
8 mg 1 times / day multiple, topical Recommended Dose: 8 mg, 1 times / day Route: topical Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.1, p.5 |
unhealthy Health Status: unhealthy Condition: Advanced-stage Parkinson’s disease Sources: Page: p.1, p.5 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 51.0 |
no | |||
Page: 51.0 |
no | |||
Page: 51.0 |
no | |||
Page: 51.0 |
no | |||
Page: 51.0 |
no | |||
Page: 51.0 |
no | |||
Page: 51.0 |
no | |||
Page: 51.0 |
no | |||
Page: 51.0 |
no | |||
Page: 50.0 |
no | no (co-administration study) Comment: rotigone did not influence the transport of digoxin Page: 50.0 |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 27.0 |
minor [Km >1000 uM] | |||
Page: 27.0 |
minor [Km >1000 uM] | |||
Page: 27.0 |
no | |||
Page: 27.0 |
no | |||
Page: 27.0 |
no | |||
Page: 27.0 |
no | |||
Page: 27.0 |
no | |||
Page: 27.0 |
no | |||
Page: 27.0 |
no | |||
Page: 27.0 |
no | |||
Page: 42.0 |
yes | |||
Page: 42.0 |
yes | |||
Page: 42.0 |
yes | |||
Page: 25.0 |
yes | |||
Page: 27.0 |
yes | |||
Page: 27.0 |
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 42.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. | 1991 Apr 18 |
|
Affinity for dopamine D2, D3, and D4 receptors of 2-aminotetralins. Relevance of D2 agonist binding for determination of receptor subtype selectivity. | 1996 Oct 11 |
|
Further characterization of structural requirements for ligands at the dopamine D(2) and D(3) receptor: exploring the thiophene moiety. | 2002 Jul 4 |
|
Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome. | 2007 Jun |
|
[Restless-legs syndrome]. | 2008 Aug-Sep |
|
Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in Cynomolgus monkeys. | 2013 Feb |
Sample Use Guides
Parkinson’s disease: Initially, 2 mg/24 hours for early-stage disease or 4 mg/24 hours for advanced-stage disease. The dose may be increased as needed by 2 mg/24 hours at weekly intervals, up to 6 mg/24 hours for earlystage
disease and up to 8 mg/24 hours for advanced-stage disease.
Restless Legs Syndrome: Initially, 1 mg/24 hours, increased as needed by 1 mg/24 hours at weekly intervals, up to 3 mg/24 hours.
Route of Administration:
Transdermal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3569410
The binding of [3H]N-0437 (specific activity 80.6 Ci/mmol) to calf caudate membranes is described. It was found that [3H]N-0437 binds with a high affinity (KD = 0.17 nM) and a low proportion of non-specific binding.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:43:47 GMT 2023
by
admin
on
Fri Dec 15 15:43:47 GMT 2023
|
Record UNII |
87T4T8BO2E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
NEUPRO (AUTHORIZED: PARKINSON DISEASE)
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
||
|
WHO-ATC |
N04BC09
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
NEUPRO (AUTHORIZED: RESTLESS LEGS SYNDROME)
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
LEGANTO (AUTHORIZED: RESTLESS LEGS SYNDROME)
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
||
|
WHO-VATC |
QN04BC09
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
||
|
NCI_THESAURUS |
C66884
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
LEGANTO (AUTHORIZED: PARKINSON DISEASE)
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
QQ-05
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
PRIMARY | |||
|
941
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
PRIMARY | |||
|
100000089581
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
PRIMARY | |||
|
7897
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
PRIMARY | |||
|
59227
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
PRIMARY | |||
|
87T4T8BO2E
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
PRIMARY | |||
|
DB05271
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
PRIMARY | |||
|
87T4T8BO2E
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
PRIMARY | |||
|
616739
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
PRIMARY | RxNorm | ||
|
ROTIGOTINE
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
PRIMARY | |||
|
SUB21254
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
PRIMARY | |||
|
8254
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
PRIMARY | |||
|
Rotigotine
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
PRIMARY | |||
|
1606060
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
PRIMARY | |||
|
C77566
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
PRIMARY | |||
|
99755-59-6
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
PRIMARY | |||
|
CHEMBL1303
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
PRIMARY | |||
|
m9674
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
PRIMARY | Merck Index | ||
|
2407
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
PRIMARY | |||
|
DTXSID5046772
Created by
admin on Fri Dec 15 15:43:47 GMT 2023 , Edited by admin on Fri Dec 15 15:43:47 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
EXCRETED UNCHANGED |
URINE
|
||
|
TARGET -> AGONIST |
|
||
|
TARGET -> AGONIST |
SHORT-ACTING
|
||
|
TARGET -> AGONIST | |||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> AGONIST |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
two UDP-glucuronosyltransferases catalyze the metabolism of rotigotine
|
||
|
METABOLITE -> PARENT |
MAJOR
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
MAJOR
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
sulfotransferases
|
||
|
METABOLITE -> PARENT |
MAJOR
PLASMA; URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
below LOQ (300 dpm/ml)
MINOR
URINE
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||